Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in Mozambique
Not Applicable
- Conditions
- Poliovirus
- Registration Number
- PACTR202404654347323
- Lead Sponsor
- World Health Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 888
Inclusion Criteria
?Healthy child aged 6-59 months old
?Resident in study area for the duration of the study period
?Parent/guardian consent for participation in the study
?Child included in nOPV2 study or their brothers, cousins, neighbour children
Exclusion Criteria
?Health issue contraindication for venepuncture
?Acutely sick child or child requiring hospitalization.
?Diagnosis or suspicion of congenital immunodeficiency disorder in the subject or an immediate family member
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare type 2 immunogenicity of two doses of nOPV2 administered alone to two doses of nOPV2 co-administered with mOPV1 and two doses of nOPV2 co-administered with bOPV.
- Secondary Outcome Measures
Name Time Method To compare type 1 and type 3 immunogenicity of two doses of nOPV2 administered alone to two doses of nOPV2 co-administered with mOPV1 and two doses of nOPV2 co-administered with bOPV. ;To compare type 1, type 2 and 3 immunogenicity of three doses of nOPV2 administered alone to three doses of nOPV2 co-administered with mOPV1 and three doses of nOPV2 co-administered with bOPV.